Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272–277.

• PubMed
Klotz L, Vesprini D, Sethukavalan P, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272–277.)| false
• Search Google Scholar
• Export Citation

Reese AC, Pierorazio PM, Han M, et al. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012;80:1075–1079.

• PubMed
Reese AC, Pierorazio PM, Han M, Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012;80:1075–1079.)| false
• Search Google Scholar
• Export Citation

Nguyen PL, Haddad Z, Ross AE, et al. Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens. Eur Urol 2017;72:845–852.

• PubMed
Nguyen PL, Haddad Z, Ross AE, Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens. Eur Urol 2017;72:845–852.)| false
• Search Google Scholar
• Export Citation

Spratt DE, Zhang J, Santiago-Jiménez M, et al. Development and validation of a novel integrated-genomic risk group classification for localized prostate cancer. J Clin Oncol 2018;36:581–590.

• PubMed
Spratt DE, Zhang J, Santiago-Jiménez M, Development and validation of a novel integrated-genomic risk group classification for localized prostate cancer. J Clin Oncol 2018;36:581–590.)| false
• Search Google Scholar
• Export Citation

Vince RA Jr, Jiang R, Qi J, et al. Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis 2022;25:677–683.

• PubMed
Vince RA Jr, Jiang R, Qi J, Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer Prostatic Dis 2022;25:677–683.)| false
• Search Google Scholar
• Export Citation

Klein EA, Cooperberg MR, Magi-Galluzzi C, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550–560.

• PubMed
Klein EA, Cooperberg MR, Magi-Galluzzi C, A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66:550–560.)| false
• Search Google Scholar
• Export Citation

Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014;192:409–414.

• PubMed
Bishoff JT, Freedland SJ, Gerber L, Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol 2014;192:409–414.)| false
• Search Google Scholar
• Export Citation

Cooperberg MR, Cowan JE, Lindquist KJ, et al. Multiple tissue biomarkers independently and additively predict prostate cancer pathology outcomes. Eur Urol 2021;79:141–149.

• PubMed
Cooperberg MR, Cowan JE, Lindquist KJ, Multiple tissue biomarkers independently and additively predict prostate cancer pathology outcomes. Eur Urol 2021;79:141–149.)| false
• Search Google Scholar
• Export Citation

Spratt DE, Liu VYT, Michalski J, et al. Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370–377.

• PubMed
Spratt DE, Liu VYT, Michalski J, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial. Int J Radiat Oncol Biol Phys 2023;117:370–377.)| false
• Search Google Scholar
• Export Citation

Nguyen PL, Huang HR, Spratt DE, et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials. Int J Radiat Oncol Biol Phys 2023;116:521–529.

• PubMed
Nguyen PL, Huang HR, Spratt DE, Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials. Int J Radiat Oncol Biol Phys 2023;116:521–529.)| false
• Search Google Scholar
• Export Citation

Schaeffer EM, Srinivas S, Adra N, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. Version 3.2024. Accessed April 2, 2024. To view the most recent version, visit https://www.nccn.org

• PubMed
Schaeffer EM, Srinivas S, Adra N, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. Version 3.2024. Accessed April 2, 2024. To view the most recent version, visit https://www.nccn.org)| false
• Search Google Scholar
• Export Citation

Ross AE, Johnson MH, Yousefi K, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 2016;69:157–165.

• PubMed
Ross AE, Johnson MH, Yousefi K, Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 2016;69:157–165.)| false
• Search Google Scholar
• Export Citation

Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phae III clinical trials. NPJ Digit Med 2022;5:71.

• PubMed
Esteva A, Feng J, van der Wal D, Prostate cancer therapy personalization via multi-modal deep learning on randomized phae III clinical trials. NPJ Digit Med 2022;5:71.)| false
• Search Google Scholar
• Export Citation

Spratt DE, Tang S, Sun Y, et al. Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid 2023;2:EVIDoa2300023.

• PubMed
Spratt DE, Tang S, Sun Y, Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid 2023;2:EVIDoa2300023.)| false
• Search Google Scholar
• Export Citation